Esomeprazole Magnesium
Development and Validation of Simple Titrimetric Method for the Determination of Magnesium Content in Esomeprazole Magnesium
5
Analytical Method Development and Validation for Simultaneous Estimation of Naproxen and Esomeprazole Magnesium in Tablet Dosage form by RP-HPLC
93
Physico chemical characterization, UV spectrophotometric method development and validation studies of Esomeprazole Magnesium Trihydrate
7
FORMULATION AND EVALUATION OF BILAYERED TABLETS OF DICLOFENAC SODIUM AND ESOMEPRAZOLE MAGNESIUM A DUAL THERAPY FOR PEPTIC ULCER
21
Esomeprazole Magnesium Trihydrate Drug as a Potential Non Toxic Corrosion Inhibitor for Mild Steel in Acidic Media
18
Development and Validation of Genotoxic Impurity in Esomeprazole Magnesium Trihydrate Active Pharmaceutical Ingredient by LC-MS/MS
8
Formulation And Evaluation Of Esomeprazole Magnesium Controlled Release Multiple Unit Matrix Pellets By Extrusion And Spheronization Technology
5
Development and validation of RP-HPLC method for the simultaneous estimation of naproxen sodium and esomeprazole magnesium in pharmaceutical tablet dosage form
10
Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses
19
RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION AND FORCED DEGRADATION STUDIES OF NAPROXEN AND ESOMEPRAZOLE MAGNESIUM IN DELAYED RELEASE DOSAGE FORM
10
SIMULTANEOUS ESTIMATION OF ESOMEPRAZOLE MAGNESIUM TRIHYDRATE, ITOPRIDE HYDROCHLORIDE AND MOSAPRIDE CITRATE BY RP HPLC METHOD: OPTIMIZATION, DEVELOPMENT, VALIDATION AND APPLICATION TO LABORATORY SAMPLE
6
Method development and validation for quantitative determination of 2 acetoxy methyl 4 methoxy 3,5 dimethyl pyridine, an impurity, in esomeprazole magnesium (API) active pharmaceutical ingredient by LC ESI MS/MS
8
RP HPLC METHOD FOR THE ESTIMATION OF ESOMEPRAZOLE MAGNESIUM IN BULK AND ITS PHARMACEUTICAL DOSAGE FORMS
7
Formulation and Evaluation of Mucoadhesive Buccal Films of Esomeprazole Magnesium Trihydrate
7
DEVELOPMENT AND CHARACTERIZATION OF FLOATING MICROSPHERES OF ESOMEPRAZOLE MAGNESIUM TRIHYDRATE BY SOLVENT EVAPORATION METHOD
12
Formulation and Evaluation of Gastroretentive Floating Microspheres of Esomeprazole Magnesium Trihydrate
90
Method, Development and Validation for the Estimation of Magnesium Content in Esomeprazole-magnesium by Atomic Absorption Spectrophotometer
5
SPECTROPHOTOMETRIC SIMULTANEOUS DETERMINATION OF ASPIRIN AND ESOMEPRAZOLE MAGNESIUM IN SYNTHETIC MIXTURE BY RATIO DERIVATIVE METHOD
13
SIMULTANEOUS ESTIMATION OF DICLOFENAC SODIUM AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE IN BULK DRUG AND IN SYNTHETIC MIXTURE BY SPECTROPHOTOMETRY
6
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO<sup>®</sup> (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
9